Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma

Experimental and Therapeutic Medicine

Volumn 2, Issue 4, 2011, Pages 647-653

  Wu, Wen Yong ^a   Li, Jun ^a   Wu, Zheng Sheng ^a   Zhang, Chang Le ^a   Meng, Xiang Ling ^a   Lobie, Peter E ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Hepatocellular carcinoma; Phosphorylated signal transducer and activator of transcription 3; Prognosis; Suppressor of cytokine signaling 3

Indexed keywords

KI 67 ANTIGEN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; VASCULOTROPIN;

ADULT; ARTICLE; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TUMOR VOLUME;

EID: 79958036438     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.254     Document Type: Article

References (31)

1. He J, Gu D, Wu X, et al: Major causes of death among men and women in China. N Engl J Med 353: 1124-1134, 2005.
2. Hirano T, Ishihara K and Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19: 2548-2556, 2000.
3. Valentino L and Pierre J: JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71: 713-721, 2006.
4. Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954, 2002.
5. Bowman T, Garcia R, Turkson J and Jove R: STATs in onco-genesis. Oncogene 19: 2474-2488, 2000.
6. Yu H and Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004.
7. Kanda N, Seno H, Konda Y, et al: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23: 4921-4929, 2004.
8. Choi JH, Ahn MJ, Park CK, Han HX, Kwon SJ, Lee YY and Kim IS: Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray. APMIS 114: 619-625, 2006.
9. Yang SF, Wang SN, Wu CF, Yeh YT, Chai CY, Chunag SC, Sheen MC and Lee KT: Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol 60: 642-648, 2007.
10. Deng JY, Sun D, Liu XY, Pan Y and Liang H: STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol 16: 5380-5387, 2010.
11. Kim HS, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J and Ahn MJ: Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer 116: 676-685, 2010.
12. Huang WT, Yang SF, Wu CC, Chen WT, Huang YC, Su YC and Chai CY: Expression of signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 in urothelial carcinoma. Kaohsiung J Med Sci 25: 640-646, 2009.
13. Kile BT and Alexander WS: The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci 58: 1627-1635, 2001.
14. Bai L, Yu Z, Qian G, Qian P, Jiang J, Wang G and Bai C: SOCS3 was induced by hypoxia and suppressed STAT3 phosphorylation in pulmonary arterial smooth muscle cells. Respir Physiol Neurobiol 152: 83-91, 2006.
15. O'Shea JJ, Gadina M and Schreiber RD: Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109: S121- S131, 2002.
16. Edmondson HA and Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer 7: 462-503, 1954.
17. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F and Xu XC: Prognostic signifcance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 122: 2050-2056, 2008.
18. Wu ZS, Wu Q, Wang CQ, Wang XN, Wang Y, Zhao JJ, Mao SS, Zhang GH, Zhang N and Xu XC: MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer 10: 542, 2010.
19. Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ and van der Woude CJ: Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59: 227-235, 2010.
20. Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathology 40: 2-11, 2002.
21. Yang SF, Yeh YT, Wang SN, Hung SC, Chen WT, Huang CH and Chai CY: SOCS-3 is associated with vascular invasion and overall survival in hepatocellular carcinoma. Pathology 40: 558-563, 2008.
22. Niu G, Wright KL, Huang M, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
23. Alexander WS and Hilton DJ: The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22: 503-529, 2004.
24. Yoshimura A, Nishinakamura H, Matsumura Y and Hanada T: Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther 7: 100-110, 2005.
25. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F and Jablons DM: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100: 14133-14138, 2003.
26. Yu ZB, Bai L, Qian P, Xiao YB, Wang GS, Qian GS, Bai CX and Min JX: Restoration of SOCS3 suppresses human lung adeno-carcinoma cell growth by downregulating activation of Erk1/2, Akt apart from STAT3. Cell Biol Int 33: 995-1001, 2009.
27. Croker BA, Krebs DL, Zhang JG, et al: SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4: 540-545, 2003.
28. Ying M, Li D, Yang L, Wang M, Wang N, Chen Y, He M and Wang Y: Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. J Cancer Res Clin Oncol 136: 1617-1626, 2010.
29. Nakagawa T, Iida S, Osanai T, Uetake H, Aruga T, Toriya Y, Takagi Y, Kawachi H and Sugihara K: Decreased expression of SOCS-3 mRNA in breast cancer with lymph node metastasis. Oncol Rep 19: 33-39, 2008.
30. Sakai I, Takeuchi K, Yamauchi H, Narumi H and Fujita S: Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100: 2926 -2931, 2002.
31. Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C, Wasik M and Ødum N: Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 19: 209-213, 2005.